Accretion Nutraveda Limited has finalized the details for its upcoming initial public offering. The bidding window will be open from January 27 to January 30, 2026. The issue is entirely a fresh offering of 19.20 lakh shares with a price band fixed at ₹122 to ₹129 per share.
The company operates a state-of-the-art facility in Sanand, Gujarat, producing a wide range of products including tablets, capsules, and oils focused on liver care, women's health, and respiratory wellness. Accretion Nutraveda has established a strong international footprint, exporting to over 20 countries, including the USA, Singapore, and Sri Lanka.
Financially, the company has reported an explosive growth trajectory. Its revenue surged from ₹3.07 crore in FY23 to ₹16.06 crore in FY25, with a corresponding jump in Profit After Tax (PAT) from ₹0.28 crore to ₹2.61 crore. As of today, January 22, 2026, the Grey Market Premium (GMP) is currently not active (trading at ₹0), as market participants wait for the anchor book results and official subscription opening.
Key IPO Details & Timetable
| Feature | Details |
| Price Band | ₹122 – ₹129 per share |
| Lot Size | 1,000 Shares (Min. Investment ₹2,58,000 for Retail*) |
| Total Issue Size | ₹24.77 Crore (100% Fresh Issue) |
| Listing Platform | BSE SME |
| Open Date | January 27, 2026 (Tuesday) |
| Close Date | January 30, 2026 |
| Basis of Allotment | February 2, 2026 |
| Tentative Listing | February 4, 2026 |
*Note: Retail investors must apply for a minimum of 2 lots (2,000 shares) due to the total application value requirements for this issue.
Important Note for Investors
-
Stellar Return Ratios: The company boasts an exceptionally high Return on Equity (ROE) of 81.22% and a ROCE of 36.98% for FY25, indicating high efficiency in generating profits from its capital base.
-
Valuation Watch: At the upper price band of ₹129, the IPO is priced at a P/E ratio of approximately 35.75x based on FY25 earnings. Some analysts have labeled the pricing as "exorbitant" compared to peers like Walpar Nutritions, suggesting investors should be cautious.
-
Aggressive Expansion: A significant portion of the proceeds (₹8.03 crore) is earmarked for a brand-new manufacturing setup. However, the company is yet to place final orders for the machinery, which poses a minor risk of project delay.
-
Customer Concentration: Despite its global reach, the company remains dependent on a limited number of major customers for a significant portion of its sales. The loss of any major client could impact short-term profitability.
Loading comments...